SPARCL1 is an angiocrine inhibitor of tumorigenesis in colorectal carcinoma

Tenkerian C, Regensburger D, Langer V, Klingler A, Borau A, Sticht H, Ramming A, Wohlfahrt T, Schmid B, Meniel V, Grützmann R, Britzen-Laurent N, Schellerer V, Stürzl M, Naschberger E (2019)

Publication Type: Conference contribution

Publication year: 2019

Journal

Cancer Research American Association for Cancer Research

Publisher: AMER ASSOC CANCER RESEARCH

City/Town: PHILADELPHIA

Conference Proceedings Title: CANCER RESEARCH

Event location: Atlanta, GA US

DOI: 10.1158/1538-7445.AM2019-195

Authors with CRIS profile

Daniela Regensburger Department of Surgery Victoria Pürzer Professur für Molekulare und Experimentelle Chirurgie Heinrich Sticht Professur für Bioinformatik Robert Grützmann Lehrstuhl für Allgemein- und Viszeralchirurgie Nathalie Britzen-Laurent Professur für Molekulare und Experimentelle Chirurgie Vera Schellerer Department of Surgery Michael Stürzl Professur für Molekulare und Experimentelle Chirurgie Elisabeth Naschberger Medizinische Fakultät

Involved external institutions

European Cancer Stem Cell Research Institute GB United Kingdom (GB)

How to cite

APA:

Tenkerian, C., Regensburger, D., Langer, V., Klingler, A., Borau, A., Sticht, H.,... Naschberger, E. (2019). SPARCL1 is an angiocrine inhibitor of tumorigenesis in colorectal carcinoma. In CANCER RESEARCH. Atlanta, GA, US: PHILADELPHIA: AMER ASSOC CANCER RESEARCH.

MLA:

Tenkerian, Clara, et al. "SPARCL1 is an angiocrine inhibitor of tumorigenesis in colorectal carcinoma." Proceedings of the AACR Annual Meeting on Bioinformatics, Convergence Science, and Systems Biology, Atlanta, GA PHILADELPHIA: AMER ASSOC CANCER RESEARCH, 2019.

BibTeX: Download